Business
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR
About this update from Proqr Therapeutics N.v.
[{"type":"text","content":"ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR’s first AI-discovered Development Candidate expected to enter the clinic in 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board. The company will host a virtual Investor and Analyst event on April 8, 2026 at 10am EDT where it will further discuss these developments as part of a broader update on its pipeline and platform. “Over the last 18 months we have developed an AI model that leads to significant acceleration and improvement of editing oligonucleotides in drug discovery,” said Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “We welcome the distinguished members of our AI advisory board who are helping us to maximize the impact of AI-enabled drug discovery for patients.” De Boer continued, “We’re pleased to have announced the partnership with Ginkgo Bioworks, providing us access to their state-of-the-art autonomous lab enabling high throughput data generation to further scale up our AI-enabled drug discovery.” Strategic Partnership with Ginkgo Bioworks ProQR’s partnership with Ginkgo Bioworks provides ProQR access to Ginkgo’s 50+ instrument autonomous lab, Nebula. Ginkgo’s autonomous lab removes a main bottleneck in AI-enabled drug discovery by increasing data generation throughput and speed. This capability is expected to increase the scale and speed of experimental data generation, enabling more efficient discovery timelines and improving the ability of ProQR’s discovery AI models to predict drug candidates. Ginkgo made a strategic equity investment in ProQR in connection with the partnership. AI-enabled Programs ProQR expects to advance its first programs generated using its AI-enabled discovery approach into the clinic, with a clinical trial application (CTA) anticipated in mid-2026 and initial clinical ...